Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company’s web site at www.vyteris.com.
- 18 years ago
QualityStocks
Vyteris, Inc. (OTC BB: VYTR)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…